407294
αA-Interferon, Human, Recombinant, E. coli
別名:
IFNA2A, IFNA2B, IFNA2C, rhIFN-αA
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
NACRES:
NA.77
UNSPSC Code:
12352202
Form:
liquid
Assay:
≥95% (SDS-PAGE)
description
Merck USA index - 14, 4990
Quality Segment
assay
≥95% (SDS-PAGE)
form
liquid
specific activity
≥2.8 x 108 units/mg protein, ≥5 x 106 units/mL
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
technique(s)
cell based assay: suitable
solubility
soluble (Dilute only in buffers containing protein such as 0.1% BSA.)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−70°C
Gene Information
human ... IFNA1(3340)
General description
Research area: Immunoand cks
Interferons are cytokines secreted by mammalian cells. They are broadly divided into type I– interferon alpha (IFN-α) and interferon beta (IFN-β), type II – interferon-gamma (IFN-γ), and type III – interferon lambda (IFN-λ) based on their structure, function, and receptor specificity. Recombinant αA interferon is a hydrophobic protein belonging to the IFN-α family of proteins.
Interferons are cytokines secreted by mammalian cells. They are broadly divided into type I– interferon alpha (IFN-α) and interferon beta (IFN-β), type II – interferon-gamma (IFN-γ), and type III – interferon lambda (IFN-λ) based on their structure, function, and receptor specificity. Recombinant αA interferon is a hydrophobic protein belonging to the IFN-α family of proteins.
Application
Interferon alpha has been used to evaluate its effect on VSV (vesicular stomatitis virus) infection in pancreatic ductal adenocarcinoma (PDA) cell lines and study the relationship between type I IFNsignaling, resistance to VSV infection, and the JAK/STAT (Janus kinase/signal transducers and activators of transcription) signaling pathways in PDA cell lines. It has also been used to study the inhibitory effect of Morbillivirus V Proteins on Interferon Signaling Pathways.
Biochem/physiol Actions
Recombinant, human αA-interferon expressed in E. coli have antiviral, antiproliferative, antineoplastic, and immunomodulating properties. Recombinant interferon αA (IFN-αA) is used as the first line of treatment for hepatitis C. It also displays a great therapeutic potential with chronic viral hepatitis, polycythemia, leukemia, and various other malignancies. It enhances natural killer cell activity, suppresses bone marrow function, and induces apoptotic cell death in non-melanoma skin cancer.
Physical form
In PBS containing 0.1% BSA.
Preparation Note
Dilute only in buffers containing protein such as 0.1% BSA.
Following initial thaw, aliquot and freeze (-70°C).
Other Notes
Fujishima, H., et al. 1998. Int. J. Cancer 76, 423.
Haria, M., and Benfield, P. 1995. Drugs 50, 873.
Familletti, P.C., et al. 1981. Methods Enzymol. 78, 387.
Haria, M., and Benfield, P. 1995. Drugs 50, 873.
Familletti, P.C., et al. 1981. Methods Enzymol. 78, 387.
One unit of interferon per ml of medium will cause a 50% inhibition of VSV-induced cytopathic effect on bovine MDBK cells. Units are determined with respect to the NIH international reference standard for human αA-IFN. Dilute in aqueous buffer containing at least 0.1% BSA or HSA.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。